IDH2 and neoplasm: As a result, future studies with a larger study cohort that can further assess the associations of age, tumor grade, 1p/19q co-deletion status, glioma recurrence status, contrast enhancement, prior treatments, and overall survival would be valuable to better understand the findings of this present study and, more broadly, add to the present study’s findings on interpreting the radiographic response to IDH inhibitors in patients with IDH1-mutant gliomas.